IMUX

Immunic is a pre-revenue, clinical-stage biotech whose entire value rests on one asset: vidofludimus calcium (IMU-838), now in the Phase 3 ENSURE trials for relapsing MS. The MD&A is explicit that the company has 'incurred net losses since inception,' carries a $608.6M accumulated deficit, has 'no product sales revenue and may never generate product revenue,' and 'will require substantial additional capital.' There is no fundamental floor here — no revenue in any year FY2021–FY2025, and losses that have hovered near $90–120M annually. This is a research bet on a trial outcome, not a business with durable economics.

The balance sheet is broken and screams financing distress. FY2025 ended with just $15.5M cash (down 56.6% YoY) against an $85.8M annual operating cash burn — well under three months of runway on its own — and stockholders' equity is negative at -$6.67M (liabilities/equity of -4.60x). The company plugged this in February 2026 with a ~$200M private placement, but the structure is telling: it is built on pre-funded and common warrants tied to the ENSURE 'Topline Data Announcement,' alongside a reverse stock split (the $0.87 warrant pricing implies a pre-split sub-$1 stock and the disclosed Nasdaq $1.00 minimum-bid delisting risk). Much of that $200M is contingent exercise capital, not cash in the bank today, and it comes on top of a share count that already grew 44.7% YoY to 130M — dilution is the recurring funding model.